Document is current
Any future updates will be listed below
-
Authors
Kleinendorst, Simone C. https://orcid.org/0000-0002-2664-9428
Hooijmans, Carlijn R. https://orcid.org/0000-0001-6435-5714
Muselaers, Stijn https://orcid.org/0000-0001-6906-7033
Oosterwijk, Egbert https://orcid.org/0000-0001-5049-0018
Konijnenberg, Mark https://orcid.org/0000-0001-5895-8500
Heskamp, Sandra https://orcid.org/0000-0001-7250-0846
van Lith, Sanne A. M. https://orcid.org/0000-0001-8584-2546
-
Funding
Funding for this research was provided by:
ZonMw (01142042330012)
KWF Kankerbestrijding (2019-2, 12567)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (09150172010054, 09150162310086)
- License Information
-
More Information
Article History
Received: 6 March 2025
Accepted: 14 April 2025
First Online: 26 April 2025
Declarations
:
: Not applicable.
: SH and SCK are inventors on a patent involving the combination of [177Lu]Lu-DOTA-hG250 with immune checkpoint inhibitor therapy. The other authors declare that they have no competing interests.
